Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Actemra in steroid-refractory acute graft versus host disease
NCT01757197Phase 2Terminated
- Sponsor
- Weill Cornell Medicine
- Start
- Nov 2013
- Primary completion
- Jun 2014
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of tocilizumab in graft-versus-host disease (GVHD), sponsored by Weill Cornell Medicine. Started Nov 2013; status: terminated.
02
Drugs
tocilizumab
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT01757197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01757197.